A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumours

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Liver cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 06 Jun 2017 Results assessing correlation between pretreatment liver metastases and survival in durvalumab treated non-small cell lung cancer patients in two independent clinical trials (CP1108/NCT01693562 and ATLANTIC/NCT02087423), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Updated safety and efficacy results (n=191, data cutoff date:24 Oct 2016) of durvalumab in locally advanced or metastatic urothelial carcinoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 06 Jun 2017 Results of an interim analysis (n=40, as of 24 Oct 2016) from the hepatocellular carcinoma cohort in the dose-expansion part of this study, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top